Dr. Omoshile Clement is a seasoned life sciences and diagnostics leader with more than 20 years of experience advancing cancer testing technologies, molecular diagnostics, and early detection solutions. His career spans global roles at industry-defining organizations such as American Type Culture Collection (ATCC), LGC Clinical Diagnostics, Bio-Rad Laboratories, Illumina, Asuragen, and RainDance Technologies.
Across these roles, Dr. Clement has led the development, commercialization, and global adoption of innovative cancer diagnostics — from qPCR and NGS assays to digital biology platforms, liquid biopsy tools, and biomarker-driven early detection technologies. He was the commercial lead in the global launch of the first FDA-cleared chronic myeloid leukemia (CML) monitoring assay for BCR-ABL break point, directed the creation of targeted NGS sequencing panels for solid tumors and hematologic malignancies, and oversaw the release of clinical genomics products for oncology and immuno-oncology diagnostics, patient stratification, and residual disease monitoring assays.
A recognized collaborator across the oncology ecosystem, Dr. Clement has convened and managed blue-ribbon advisory panels of MDs and MD/PhDs in hematology-oncology, molecular pathology, and solid tumor diagnostics. His leadership has shaped assays and technologies used in cancer detection, prognostic assessment, relapse monitoring, and biomarker-based precision medicine.
As Founder and Executive Director of HopeScan Initiative Inc., Dr. Clement brings this deep technical and strategic expertise to the mission of expanding access to early cancer detection and treatment in underserved regions of West Africa. His work focuses on deploying modern diagnostic approaches — diagnostic equipment, liquid biopsy biomarker-based testing, clinical patient sample collection kits, molecular assays, and community-anchored screening models — to ensure that preventable cancers are detected early, treated promptly, and no longer allowed to claim lives due to lack of access.
Dr. Clement earned his BS (Honors) in Chemistry from the University of Ibadan in Nigeria, an MS/PhD in Chemistry from Queen’s University in Ontario, Canada, as a C.I.D.A. scholar, and an AWU/PNNL postdoctoral research fellowship conducted in the Environmental Molecular Sciences Laboratory (EMSL) at the Pacific Northwest National Laboratory (PNNL), in Richland, Washington, USA.
Omo has built and led high-performing product organizations, including global teams of product managers, specialists, scientists, and market analysts. He has managed large-scale biomaterial repositories of over 100,000 cellular and microbial materials used in cancer research, therapeutic development, and diagnostic innovation. His work has consistently bridged scientific rigor with market insight — leveraging market opportunity & intel data, competitive analytics, and clinical partnerships to guide product strategy and accelerate adoption.
A recognized collaborator across the oncology ecosystem, Omo has convened and led blue-ribbon advisory panels of MDs and MD/PhDs in hematology-oncology, molecular pathology, and solid tumor diagnostics. His leadership has shaped assays and technologies used in cancer detection, prognostic assessment, relapse monitoring, and biomarker-based precision medicine.
Today, as Founder and Executive Director of HopeScan Initiative, Omo brings this deep technical and strategic expertise to the mission of expanding access to early cancer detection across Africa. His work focuses on deploying modern diagnostic approaches — including liquid biopsy biomarkers, molecular assays, and community-anchored screening models — to ensure that preventable cancers are detected early, treated promptly, and no longer allowed to claim lives due to lack of access.
Omo’s career reflects a singular commitment: advancing innovative cancer diagnostics and ensuring that lifesaving early detection reaches every community, regardless of geography or resources.
A recognized collaborator across the oncology ecosystem, Dr. Clement has convened and managed blue-ribbon advisory panels of MDs and MD/PhDs in hematology-oncology, molecular pathology, and solid tumor diagnostics. His leadership has shaped assays and technologies used in cancer detection, prognostic assessment, relapse monitoring, and biomarker-based precision medicine.
As Founder and Executive Director of HopeScan Initiative Inc., Dr. Clement brings this deep technical and strategic expertise to the mission of expanding access to early cancer detection and treatment in underserved regions of West Africa. His work focuses on deploying modern diagnostic approaches — diagnostic equipment, liquid biopsy biomarker-based testing, clinical patient sample collection kits, molecular assays, and community-anchored screening models — to ensure that preventable cancers are detected early, treated promptly, and no longer allowed to claim lives due to lack of access.
Dr. Clement earned his BS (Honors) in Chemistry from the University of Ibadan in Nigeria, an MS/PhD in Chemistry from Queen’s University in Ontario, Canada, as a C.I.D.A. scholar, and an AWU/PNNL postdoctoral research fellowship conducted in the Environmental Molecular Sciences Laboratory (EMSL) at the Pacific Northwest National Laboratory (PNNL), in Richland, Washington, USA.
